Drug News

ViroKey SARS-CoV-2 RT-PCR Test receives the CE mark for in vitro diagnostic test for COVD-19.- Vela Diagnostics

Read time: 1 mins

Published:25th Apr 2020

Vela Diagnostics announced that the manual version of the ViroKey SARS-CoV-2 RT-PCR Test has received the CE mark for in vitro diagnostic use. The test detects SARS-CoV-2 in patients suspected of COVID-19 by their healthcare providers. The ViroKey SARS-CoV-2 RT-PCR Test is a probe-based reverse transcription PCR Test that detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome. The manual version of the assay enables quick adoption of the test by laboratories with existing Applied Biosystems 7500 Fast Dx (ABI 7500 Fast Dx) instruments. Vela Diagnostics has also developed an automated version of the test which is slated for CE-IVD registration in April 2020. The automated ViroKey SARS-CoV-2 RT-PCR Test is optimized for a workflow consisting of the Sentosa SX101 instrument, in conjunction with the Sentosa SA201 instrument or the ABI 7500 Fast Dx.

Condition: Coronavirus/COVID-19 Infection

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA issues emergency use authorisation of Pemgarda (pemivibart) (formerly VYD 222) for pre-exposure prophylaxis of COVID 19,- Invivyd Inc.

Invivyd, Inc. a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that Pemgarda (pemivibart), formerly VYD 222, a half-life extended monoclonal antibody (mAb), has received emergency use authorization (EUA) from the FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.

3 mins

Drug news

New data from three real-world retrospective studies of Veklury (remdesivir) are presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

Gilead Sciences, Inc. announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

2 min

Drug news

MHLW (Japan) grants full approval for Xocova ( ensitrelvir) to treatSARS-CoV-2 infection in Japan

Shionogi & Co., Ltd. announced that it has obtained standard approval from the Ministry of Health, Labour and Welfare (MHLW) for Xocova (Generic name: ensitrelvir fumaric acid), a novel anti-SARS-CoV-2 drug for the indication of SARS-CoV-2 infection in Japan

1 min

See all news